Catherine A. Schnabel

TL;DR: This prospective comparison study compared the prognostic ability of the breast-cancer index (BCI) assay, 21-gene recurrence score (Oncotype DX), and an immunohistochemical prognostic model (IHC4) for both early and late recurrence in patients with oestrogen-receptor-positive, node-negative breast cancer who took part in the Arimidex, Tamoxifen, Alone or in Combination clinical trial.

TL;DR: A within-patient comparison of the prognostic value of 6 multigene signatures in women with early ER-positive breast cancer who received endocrine therapy for 5 years found the ROR, BCI, and EPclin were significantly more prognostic for overall and late distant recurrence.

TL;DR: The prognostic sustainability of BCI to assess early- and late-distant recurrence risk at diagnosis has clinical use for decisions of chemotherapy at diagnosis and for decisions for extended adjuvant endocrine therapy beyond five years.

TL;DR: In the absence of extended letrozole therapy, high H/I identifies a subgroup of ER-positive patients disease-free after 5 years of tamoxifen who are at risk for late recurrence.

TL;DR: Using a molecular test followed by tailored systemic treatment did not improve outcomes of pts with CUP, and results suggest that at least 1/3 of identified primaries may not be sensitive to empiric chemotherapy used in CUPs.